Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biomed Khim ; 62(6): 725-728, 2016 Nov.
Artigo em Russo | MEDLINE | ID: mdl-28026819

RESUMO

Human immunodeficiency virus first type (HIV-1) is a main cause of one of the most dangerous diseases, AIDS. The search for new inhibitors of the virus still remains an urgent task. One approach to suppress the HIV infection is to use a double-acting inhibitors, i.e. inhibitors directed to two stages of the viral life cycle. The catalytic domain of HIV-1 integrase has a similar spatial organization with ribonuclease (RNase H) domain of HIV-1 reverse transcriptase, and approach aimed to create HIV-1 integrase and RNase H double-acting is very promising. In this work we synthesized a series of 6-nitrobenzofuroxane derivatives and studied their ability to inhibit two viral enzymes - integrase and RNase H HIV-1.


Assuntos
Transcriptase Reversa do HIV/antagonistas & inibidores , Transcriptase Reversa do HIV/química , HIV-1/enzimologia , Oxidiazóis/química , Inibidores da Transcriptase Reversa/química , Humanos
2.
Acta Naturae ; 5(1): 63-72, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23556131

RESUMO

Human immunodeficiency virus type 1 integrase is one of the most attractive targets for the development of anti-HIV-1 inhibitors. The capacity of a series of 2,1,3-benzoxadiazoles (benzofurazans) and their N-oxides (benzofuroxans) selected using the PASS software to inhibit the catalytic activity of HIV-1 integrase was studied in the present work. Only the nitro-derivatives of these compounds were found to display inhibitory activity. The study of the mechanism of inhibition by nitro-benzofurazans/benzofuroxans showed that they impede the substrate DNA binding at the integrase active site. These inhibitors were also active against integrase mutants resistant to raltegravir, which is the first HIV-1 integrase inhibitor approved for clinical use. The comparison of computer-aided estimations of the pharmacodynamic and pharmacokinetic properties of the compounds studied and raltegravir led us to conclude that these compounds show promise and need to be further studied as potential HIV-1 integrase inhibitors.

3.
Eksp Klin Farmakol ; 75(8): 11-4, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23012989

RESUMO

It is shown that 3-(3-[1,2,4]-triazolo)-oxatriazolium-5-olate (azasidnon-6) can act directly on the vascular wall of isolated segments of caudal ventral artery of SHR rats. Using heme-dependent soluble guanyl cyclase inhibitor 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), it has been found that one of the possible mechanisms of azasidnon-6 vasodilatory action includes heme-dependent activation of a soluble form of guanylate cyclase.


Assuntos
Artérias/efeitos dos fármacos , Triazóis/farmacologia , Vasodilatação/efeitos dos fármacos , Vasodilatadores/farmacologia , Animais , Guanilato Ciclase/antagonistas & inibidores , Guanilato Ciclase/metabolismo , Heme/metabolismo , Masculino , Óxido Nítrico/metabolismo , Nitroprussiato/farmacologia , Oxidiazóis/farmacologia , Fenilefrina/farmacologia , Quinoxalinas/farmacologia , Ratos , Ratos Endogâmicos SHR , Ratos Wistar , Cauda/irrigação sanguínea , Técnicas de Cultura de Tecidos , Vasoconstritores/farmacologia
4.
Eksp Klin Farmakol ; 72(3): 13-5, 2009.
Artigo em Russo | MEDLINE | ID: mdl-19642586

RESUMO

Long-term peroral administration of the oxatriazolo-5-olate derivative azasydnon-6 leads to a decrease in the systolic arterial blood pressure in SHR rats. The hypotensive effect of azasydnon-6 is mediated by stimulation of the sGC-cGMP pathway, which triggers vasodilatation of SMC in vessels. The drug effect is inhibited by 1H-[1,2,4]oxadiazolo[4, 3-a]quinoxalin-1-one, a selective sGC inhibitor. During long-term treatment, no tolerance to azasydnon-6 is developed in isolated arterial vessels.


Assuntos
Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Triazóis/farmacologia , Vasodilatação/efeitos dos fármacos , Animais , Anti-Hipertensivos/administração & dosagem , GMP Cíclico/antagonistas & inibidores , Guanilato Ciclase/antagonistas & inibidores , Masculino , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/fisiologia , Oxidiazóis/farmacologia , Quinoxalinas/farmacologia , Ratos , Ratos Endogâmicos SHR , Receptores Citoplasmáticos e Nucleares/antagonistas & inibidores , Guanilil Ciclase Solúvel
5.
Eksp Klin Farmakol ; 71(5): 25-7, 2008.
Artigo em Russo | MEDLINE | ID: mdl-19093367

RESUMO

Intravenous administration of azasidnon-6 (oxatriazolium-5-olate derivative) induces prolonged dose-dependent decrease in arterial blood pressure in awake Wistar and SHR rats. Hypotensive effects of azasidnon-6 in SHR rats is significantly higher during inhibition of endogenous NO synthesis.


Assuntos
Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Triazóis/farmacologia , Animais , Preparações de Ação Retardada/farmacologia , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Hipertensão/metabolismo , Masculino , Óxido Nítrico/metabolismo , Ratos , Ratos Endogâmicos SHR , Ratos Wistar
6.
J Ocul Pharmacol Ther ; 17(6): 505-15, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11777174

RESUMO

Twelve compounds of N-nitropyrazoles were studied for their effects on ocular blood flow in rabbits and retinal function recovery in rat eyes after ischemic insults. Of the twelve N-nitropyrazoles examined, nine increased choroidal blood flow while five increased retinal blood flow significantly. On the other hand, all twelve compounds increased blood flow in iris and ciliary muscle without exception. As for retinal function recovery after ischemic insult in rat eyes, eight out of the twelve compounds showed more significant facilitation than the control. The structure activity relationship of the N-nitropyrazoles to increase ocular blood flow and to facilitate retinal function recovery after ischemic insults were discussed.


Assuntos
Isquemia/tratamento farmacológico , Hipertensão Ocular/tratamento farmacológico , Pirazóis/farmacologia , Retina/efeitos dos fármacos , Vasos Retinianos/efeitos dos fármacos , Animais , Corioide/irrigação sanguínea , Corioide/efeitos dos fármacos , Artérias Ciliares/efeitos dos fármacos , Feminino , Isquemia/fisiopatologia , Hipertensão Ocular/fisiopatologia , Pirazóis/química , Coelhos , Ratos , Ratos Long-Evans , Fluxo Sanguíneo Regional/efeitos dos fármacos , Retina/fisiologia , Relação Estrutura-Atividade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA